linjc16/ctgov huggingface dataset:
A Pilot Feasibility Study of Mindfulness-Oriented Recovery Enhancement With Pregnant Women With Opioid Use Disorder

Study Overview
=================
Brief Summary
-----------------
Thirty pregnant women with substance use disorder will be recruited to participate in eight sessions of MORE.

Detailed Description
-----------------
Participants will be asked to complete a battery of self-report measures and a semi-structured qualitative interview at three times points-before the intervention begins, after session four, and again after session eight. Participants will also be asked to complete self-report measures before and after each session. The primary aims of this study are as follows. Aim 1: To adapt the in-person MORE intervention for telehealth delivery. Aim 2: To assess the overall feasibility and acceptability of this telehealth intervention. Hypothesis: MORE delivered via telehealth will be both feasible and acceptable to participants.

Official Title
-----------------
The Mindful Pregnancy Study: A Pilot Feasibility Study of Mindfulness-Oriented Recovery Enhancement With Pregnant Women With Opioid Use Disorder

Conditions
-----------------
Opioid-use Disorder

Intervention / Treatment
-----------------
* Behavioral: Mindfulness-Oriented Recovery Enhancement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be pregnant. Must be able to communicate in English. Must have met criteria for opioid use disorder in the past year. Exclusion Criteria: None.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mindfulness-Oriented Recovery Enhancement via tele-health<br>Participants will be assigned to 8 weeks of Mindfulness-Oriented Recovery Enhancement delivered via tele-health. | Behavioral: Mindfulness-Oriented Recovery Enhancement<br>* MORE is a mindfulness-based intervention.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Client Satisfaction | Participants will complete the Client Satisfaction Questionnaire. | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptoms of substance use disorder | Symptoms of substance use disorder will be assessed with the Mini-International Neuropsychiatric Interview 6.0. | 8 weeks |
Electroconvulsive Therapy in Clozapine-resistant Schizophrenia

Study Overview
=================
Brief Summary
-----------------
Electroconvulsive therapy (ECT) is one of the oldest neuromodulation treatments still used in psychiatry. Only case reports and open label non-randomized studies have been published of ECT in clozapine-resistant schizophrenia patients. The purpose of this trial is to study the efficacy and cognitive effects of add-on ECT treatment (10-course) in schizophrenia patients taking clozapine.

Official Title
-----------------
Efficacy and Cognitive Effects of Electroconvulsive Therapy in Clozapine-Resistant Schizophrenia

Conditions
-----------------
Schizophrenia, Schizoaffective Disorder

Intervention / Treatment
-----------------
* Device: electroconvulsive therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosis of schizophrenia or schizoaffective disorder treatment-resistant to clozapine age 18 - 64 years capacity and willingness to give informed consent Exclusion Criteria: serious somatic illness progressive neurological illness, recent brain damage or sequela of serious brain damage ECT less than 3 months prior to this trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: ECT treatment right after recruitment<br>This group receives electroconvulsive therapy treatment right after they are recruited. | Device: electroconvulsive therapy<br>* 10-course, three times a week bilateral frontotemporal ECT<br>|
| Placebo Comparator: ECT after 4 weeks period.<br>This group receives electroconvulsive therapy treatment after 4 weeks waiting period. | Device: electroconvulsive therapy<br>* 10-course, three times a week bilateral frontotemporal ECT<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Positive and Negative Symptom Scale | Positive and Negative Symptom Scale (PANSS) is assessed two days after ECT course | 2 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
clozapine, PANSS, schizoaffective disorder, schizophrenia, treatment, ECT
Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair

Study Overview
=================
Brief Summary
-----------------
Anterior cruciate ligament reapair is a painful procedure. Single shot femoral and sciatic nerve block only last 12-16 hrs. Since dexamethasone prolongs brachial plexus block, using it in lower extremity blocks will prolong the analgesia to provide better outpatient pain relief after surgery at home.

Official Title
-----------------
A Study of the Effect of Dexamethasone on Duration of Lower Extremity Blocks With Bupivacaine in Subjects Having ACL Repair

Conditions
-----------------
Duration of Pain Relief

Intervention / Treatment
-----------------
* Drug: dexamethsone
* Drug: Bupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-75, no contraindication to regional anesthesia Exclusion Criteria: peripheral neuropathy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: control<br>in this group, plain bupivacaine will be used to block femoral and sciatic nerve | Drug: Bupivacaine<br> <br> |
| Experimental: Dexamethasone<br>Bupivacaine mixed with dexamethasone will be used to block femoral and sciatic nerve | Drug: dexamethsone<br> <br> Drug: Bupivacaine<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Analgesia Duration |  | 72 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
anterior cruciate ligament, block duration
Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)

Study Overview
=================
Brief Summary
-----------------
To examine the differences in health care utilization and costs between MDD patients on adjunctive aripiprazole therapy and MDD patients on other augmentation therapies.

Official Title
-----------------
Retrospective Database Study of Real World Abilify Outcomes in Major Depressive Disorder (MDD)

Conditions
-----------------
Depressive Disorder, Major

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≥1 fill for an augmentation therapy medication from Table 1 during the identification period of 01 January 2005 - 30 November 2008. 12 months of continuous enrollment with medical and pharmacy benefits each before the index date (pre-index period) and after the index date (post-index period). ≥1 medical claim with a primary International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) diagnosis for MDD (296.2x, 296.3x, 311.xx) during the pre-index period. Age ≥18 years as of the year of the pre-index period. Exclusion Criteria: No pharmacy claims for atypical antipsychotics, mood stabilizers, anxiolytics, anticonvulsants, or stimulants, during the pre-index period. No medical claims with primary or secondary diagnoses for non-MDD episodic mood disorders or schizophrenia during the pre-index or post-index periods.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Aripiprazole cohort<br> | |
| Other atypical cohort<br> | |
| Other antidepressant cohort<br> | |
| Mood stabilizer cohort<br> | |
| Stimulant cohort<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| All cause health care costs |  | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Health care costs: MDD related, mental health related |  | 12 months | 
| Health care resource utilization: All cause, MDD related, mental health related |  | 12 months | 
| Duration of index therapies |  | 12 months | 
| Medication possession ratio to evaluate adherence |  | 12 months | 
| Discontinuation of index therapies |  | 12 months | 
| Therapy switches to a non-index antidepressant or non-index augmentation therapy |  | 12 months |
Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients

Study Overview
=================
Brief Summary
-----------------
18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches. We propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.

Detailed Description
-----------------
In order to improve locoregional control and to eradicate micrometastases for patients with locally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy followed by concurrent chemoradiotherapy has been the preferred therapeutic approach.Although it would be of great advantage to identify non-responder during or immediately after therapy to formulate an alternative treatment strategy, non-invasive methods for early evaluation of therapeutic response for advanced NPC patients have not been fully evaluated. Decrease of tumor volume in anatomical images and relief of symptoms in clinical follow-up have been used in many conventional approaches to evaluate the effectiveness of therapy. However, an effective therapy could very well have resulted in early subclinical alterations in tumor physiology and biochemistry. These alterations may have occurred long before changes in the tumor mass become apparent. Thus therapeutic effect may not be assessed accurately using the conventional anatomical imaging studies, such as CT and MRI.Recent studies have shown that 18F-FDG PET, a whole-body imaging technology based on glucose metabolism, can effectively detect subclinical and clinical therapeutic responses at stages that are earlier than those detected by conventional approaches.We therefore propose to conduct a prospective study to evaluate therapeutic response using 18F-FDG PET before and after induction chemotherapy for locally advanced NPC patients.

Official Title
-----------------
Whole-Body 18F-FDG PET in Evaluating Induction Chemotherapeutic Response for Locally Advanced Nasopharyngeal Cancer Patients and Correlating With Histopathology: a Prospective Study

Conditions
-----------------
Nasopharyngeal Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: newly diagnosed locally advanced NPC patients who are receiving induction chemotherapy for treatment Exclusion Criteria: age below 18 year old pregnancy women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
NPC, Induction chemotherapy, Therapeutic response, 18F-FDG PET
Does Body Position Influence Pressure Recording by High-resolution Manometry ?

Study Overview
=================
Brief Summary
-----------------
The anorectal manometry is the gold standard in the evaluation of anorectal function. Several techniques are currently used (balloons, perfused catheters) and are always performed in the supine position. Few studies have reported the evaluation of sphincter function in the upright position, whereas symptoms of fecal incontinence occur in this position. Recently developed, high-resolution manometry, thanks to its many mechanical sensors, allows topographic analysis and evaluation of anorectal function more acurate. In addition, the rigid nature of the probe should allow stability measures / recording, which is not possible with probes perfused catheters example. We therefore propose to compare anal sphincter pressure in supine and standing, measured in high-resolution manometry.

Official Title
-----------------
Does Body Position Influence Pressure Recording by High-resolution Manometry ?

Conditions
-----------------
Anal Incontinence or Constipation

Intervention / Treatment
-----------------
* Device: anorectal manometry and high-resolution three-dimensional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Man or woman over the age of 18 years Patient referred for endoscopic ultrasound and anal manometry anorectal HR-3D which is an indication of fecal incontinence or dyschesia Exclusion Criteria: Patient age 18 Less Patient trust, guardianship, judicial protection No Written Consent Lack of social insurance History of anorectal surgery A presence of anal stenosis A setting evidence of anorectal lesion preventing the realization of the Screening Motor disability preventing the realization of the anorectal manometry 3D HR-standing situation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: patients<br> | Device: anorectal manometry and high-resolution three-dimensional<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| anal pressures measured by anorectal manometry and high-resolution three-dimensional | comparing two positions conventional position in the left lateral decubitus position with the feet. | 12 months |
Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Study of Different Outcomes and Their Predictive Factors

Study Overview
=================
Brief Summary
-----------------
Radiological response after trans arterial chemoembolization (TACE) is classified according to Modified Response Evaluation Criteria in Solid Tumors (mRECIST) to: complete response (CR) (disappearance of arterial enhancement), partial response (PR) ( at least a 30% decrease in the sum of diameters of viable enhancement), progressive disease (PD) (an increase of at least 20% in the sum of the diameters of viable enhancement, or appearance of new lesions), and stable disease (any cases that do not qualify for either partial response or progressive disease

Detailed Description
-----------------
POST-TACE response of treatment for cases of hepatocellular cancer

Official Title
-----------------
Trans-arterial Chemoembolization in Patients With Hepatocellular Carcinoma

Conditions
-----------------
Liver Cancer

Intervention / Treatment
-----------------
* Procedure: TACE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical history and examination with special stress on symptoms and signs of chronic liver disease with or without evidence of hepatic decompensation e.g. the presence of ascites and with or without evidence of complications e.g. jaundice spider naevi, bleeding varices, ascites, and lower limb edema. Laboratory findings in the form of raised bilirubin and liver enzymes, impaired coagulation profile, and/or low serum albumin. Abdominal ultrasonography revealing liver cirrhosis (coarse echopattern, attenuated hepatic veins, irregular outlines, hypertrophy of caudate lobe and/or shrunken liver, presence of focal hepatic) and presence of splenomegaly, ascites, or portal vein thrombosis (PVT). Exclusion Criteria: A patient who had surgical resection or liver transplantation Patients refuse to participate Hepatic focal lesion other than HCC

Ages Eligible for Study
-----------------
Minimum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| TACE in HCC group 1<br>the patient did undergo tace | Procedure: TACE<br>* Trans-arterial chemoembolization in patients with hepatocellular carcinoma<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Post_TACE hepatic cell failure | Frequency of liver cell failure in form of jaundice , coagulopathy and encephalopathy | 1 year |
Longitudinal Efficacy of Dental Implants in Anterior Areas

Study Overview
=================
Brief Summary
-----------------
Dental implants are used in dentistry to reestablish function and appearance to areas of the mouth where natural teeth are missing. Implants can be a good choice for almost all areas of the mouth except where the space left by missing teeth is too narrow. This is usually the case when front teeth are lost of have been missing since birth. The Maximus dental implant is the smallest implant made, just 3mm in diameter, and is especially designed to replace missing front teeth and yet be strong enough to function as a natural tooth. This study will assess the functional success of BioHorizons Maximus one-piece endosseous dental implant. We hypothesize that placement of the 3mm dental implant in areas of limited tooth-to-tooth spacing will be an efficacious tooth root replacement.

Detailed Description
-----------------
When maxillary anterior (upper front)and/or mandibular incisors are congenitally missing or lost due to other causes, the space between adjacent teeth is frequently too narrow to support traditional implant therapy and patients are often advised to fill the space with conventional fixed or removable prosthetic appliances. The one-piece titanium construction of the Maximus design is believed to retain optimal biomechanical stength while remaining small enough for use in anterior reconstruction thereby allowing access to spaces that were previously beyond the scope of implant dentistry.

Official Title
-----------------
A Study to Evaluate the Efficacy of the 3mm Maximus Dental Implant in Areas of Limited Tooth-to-tooth Spacing

Conditions
-----------------
Edentulous

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Missing anterior teeth Exclusion Criteria: Pregnancy Cigarette smoking Diabetes Mellitus Other significant medical conditions or habits likely to compromise bone healing Chronic use of medications likely to compromise bone healing

Ages Eligible for Study
-----------------
Minimum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| peri-implant bone support |  | 5 years following prosthetic attachment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Aesthetics and function |  | 5 years following prosthectic attachment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
endosseous dental implants, dental aesthetics